BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/28/2018 9:41:36 AM | Browse: 221 | Download: 93
Publication Name World Journal of Gastroenterology
Manuscript ID 39136
Country of Manuscript Source France
2018-03-29 03:58
Peer-Review Started
2018-03-29 09:15
To Make the First Decision
2018-04-27 02:04
Return for Revision
2018-04-27 06:36
2018-05-10 11:23
Second Decision
2018-05-17 09:00
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-05-18 01:41
Articles in Press
2018-05-18 01:41
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-05-22 08:57
Publish the Manuscript Online
2018-05-28 09:41
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript type Review
Article Title Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Manuscript Source Invited Manuscript
All Author List Marc Hilmi, Laurent Bartholin and Cindy Neuzillet
Author(s) ORCID Number
Marc Hilmi http://orcid.org/0000-0003-4762-6740
Laurent Bartholin http://orcid.org/0000-0002-5637-3223
Cindy Neuzillet http://orcid.org/0000-0001-7037-7477
Funding Agency and Grant Number
Correspondence To Cindy Neuzillet, MD, MSc, Doctor, Service d’Oncologie Médicale, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France. cindy.neuzillet@gmail.com
Keywords Drug therapy combination; Immunology; Hypoxia; Checkpoint inhibitor; Inflammation; Pancreatic cancer; Tumor-infiltrating lymphocyte; Transforming growth factor; Tumor microenvironment
Core Tip Checkpoint inhibitors (CPI) and other immune therapies remain inefficient when used as single agents in pancreatic ductal adenocarcinoma (PDAC). Here, we present an overview of the biological mechanisms underlying these failures and the lessons learned, giving a rationale for innovative combination therapies. In particular, the latest ongoing studies are attempting to overcome the immunosuppressive microenvironment, the basis of resistance to CPI in PDAC.
Publish Date 2018-05-28 09:41
Citation Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? World J Gastroenterol 2018; 24(20): 2137-2151
Url http://www.wjgnet.com/1007-9327/full/v24/i20/2137.htm
DOI http://dx.doi.org/10.3748/wjg.v24.i20.2137
Full Article (PDF) WJG-24-2137.pdf
Full Article (Word) WJG-24-2137.doc
Manuscript File 39136-Review.docx
Answering Reviewers 39136-Answering reviewers.pdf
Audio Core Tip 39136-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 39136-Conflict-of-interest statement.pdf
Copyright License Agreement 39136-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 39136-Language certificate.pdf
Peer-review Report 39136-Peer-review(s).pdf
Scientific Misconduct Check 39136-Scientific misconduct check.pdf
Scientific Editor Work List 39136-Scientific editor work list.pdf